A combination preparation is provided according to exemplary embodiments. The combination preparation comprises statin and cilostazol, wherein the sustained release index of cilostazol, as calculated by mathematical formula 1, is 16.652% to 28.400%.
The present invention relates to a sustained-release formulation that exhibits rapid onset of action upon oral administration while maintaining efficacy for 24 hours. The formulation comprises an immediate-release portion containing an active ingredient and an additive, and a sustained-release portion containing an active ingredient, an additive, and a release control agent, wherein the active ingredient is mosapride or a salt thereof, and the formulation has a sustained-release index of 11.704% to 18.330%, as calculated by the following mathematical formula. [Mathematical equation 1]
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
The present invention relates to a sustained-release formulation, which exhibits rapid pharmaceutical effects when orally administered and allows the pharmaceutical effects to be sustained for 24 hours, and comprises an immediate-release part, which includes an active ingredient and an additive, and a sustained-release part, which includes an active ingredient, an additive and a cellulose derivative, wherein the active ingredient is mosapride or a salt thereof and the cellulose derivative satisfies the following conditions. [Conditions] The viscosity of an aqueous solution comprising 2 wt% of the cellulose derivative satisfies 11,000 to 60,000 cps when measured at 20°C in accordance with a second viscosity measurement method using a rotational viscometer of the viscosity determination method of general test method 57 of the Korean Pharmacopoeia, article 2, number 5.
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
4.
PHARMACEUTICAL COMPOSITION FOR THYROID PROTECTION, AND PREPARATION METHOD THEREFOR
A pharmaceutical composition for thyroid protection, according to the present invention, comprises potassium iodide, an excipient and a lubricant, wherein the average particle size of potassium iodide is less than 1.0 mm. The pharmaceutical composition for thyroid protection, according to the present invention, has excellent content uniformity and rapid dissolution characteristics. A method for preparing the pharmaceutical composition for thyroid protection, according to the present invention, comprises a pulverization step, a pre-mixing step, a post-mixing step and a tableting step, enables the preparation of a pharmaceutical composition for thyroid protection having excellent amount uniformity and rapid dissolution characteristics and having ensured pharmaceutical stability during long-term storage, and reduces processing time and costs.
The present invention relates to a method for preparing a pharmaceutical composition containing dactinomycin as an active ingredient and, specifically, to a method for preparing a dactinomycin injection having improved solubility, little content loss, and enhanced process efficiency.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
The present invention relates to an inhalable pharmaceutical composition comprising budesonide or formoterol for preventing or treating COVID-19, and the composition exhibits more superb inhibitory effects on the virus than remdesivir injections and ciclesonide inhalations, which are known as therapeutic agents for COVID-19.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
The present invention relates to a stable pharmaceutical composition comprising rabeprazole or a pharmaceutically acceptable salt thereof, and sodium bicarbonate.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
8.
PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION DISEASE-19
The present invention relates to a pharmaceutical composition comprising budesonide or formoterol for preventing or treating COVID-19, and the composition exhibits more superb effects on virus inhibition than remdesivir injections and ciclesonide inhalations, which are known as therapeutic agents for COVID-19.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/325 - Acides carbamiquesAcides thiocarbamiquesLeurs anhydrides ou sels
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 31/14 - Antiviraux pour le traitement des virus ARN
9.
SUSTAINED-RELEASE METFORMIN COATED TABLET HAVING CONTROLLED RELEASE BY OSMOTIC PRESSURE
A sustained-release coating tablet comprising metformin as an active ingredient according to the present invention has a dissolution profile that is very similar to currently marketed sustained-release metformin tablets, has not only robustness to the osmotic pressure range of the human body but also an effect in which a coating layer is not torn, and has an excellent effect of increasing dosing compliance because the tablet size is small.
The present invention relates to a combination drug comprising a proton pump inhibitor and mosapride, and provides a pharmaceutical composition which shows excellent acid resistance by virtue of inclusion of an enteric-coated proton pump inhibitor, and which shows a synergistic effect of two active ingredients even with a single-tablet once-daily administration regimen. Further, the pharmaceutical composition of the present invention is a directly compressible bi-layer tablet or cored tablet dosage form and can be produced in a rapid and reliable fashion, and thus is suitable for mass production.
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
11.
HARD CAPSULE AGENT COMPRISING ENTERIC PROTON PUMP INHIBITOR AND MOSAPRIDE SUSTAINED-RELEASE FORMULATION
The present invention relates to a pharmaceutical agent comprising within a hard capsule: an enteric coated pellet containing a proton pump inhibitor as an active ingredient or a tablet containing same, and a sustained release formulation containing mosapride as an active ingredient. Even when one capsule is administered once a day, the pharmaceutical agent exhibits the same effect as that obtained upon co-administration of the proton pump inhibitor and mosapride many times.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines
12.
PHARMACEUTICAL COMPOSITION INCLUDING R-THIOCTIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND EMULSIFIER
The present invention relates to a pharmaceutical composition in a tablet form, the composition comprising R-thioctic acid or a pharmaceutically acceptable salt thereof as an active ingredient and an oil as an emulsifier and characterized by rapid disintegration and active ingredient dissolution in vivo. In addition, the composition is characterized in that the emulsifier ingredient effectively lowers the degree of gel formation and the viscosity made by the active ingredient to remarkably decrease the inhibitory activity of the gel surrounding the tablet surface against preventing a solution from penetrating into the inside of the tablet and to improve the dissolution rate of the active ingredient at a low-pH environment.
The present invention relates to an enteric-coated tablet comprising, as an active ingredient, R-thioctic acid or a pharmaceutically acceptable salt thereof. In the enteric-coated tablet of the present invention, the active ingredient does not dissolve in the stomach with low pH and starts to dissolve in the intestinal environment with high pH. Thus, the enteric-coated tablet has excellent bioavailability as compared to conventional preparations having a problem in which active ingredients are denatured in low pH environments.
A pharmaceutical composition of the present invention is characterized by containing R-thioctic acid or a pharmaceutically acceptable salt thereof as an active ingredient and additionally including an oil and a dispersion aid. In the pharmaceutical composition of the present invention, the oil forms a protective layer surrounding the active ingredient to protect the active ingredient against exposure to an acidic environment, thereby preventing the degradation of the active ingredient while the dispersion aid improves dispersibility in a dissolution liquid, thereby allowing the active ingredient to exhibit a high dissolution rate even in a low pH environment.
The present invention relates to a method for preparing a lyophilized cyclophosphamide composition, wherein 99% or more of the finally prepared lyophilized cyclophosphamide composition is reconstituted within 15 seconds when water for pharmaceutical use is injected thereinto at a ratio of 50 mL per 1 g of anhydrous cyclophosphamide, comprising a step of dissolving D-mannitol or lactose, as a lyoprotectant, and cyclophosphamide in a water solvent in a selected reaction vessel; and a lyophilized cyclophosphamide composition for injection prepared thereof.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
16.
CORE TABLET FORMULATION CONTAINING PROTON PUMP INHIBITOR AND MOSAPRIDE
The present invention relates to a core tablet formulation containing, as active ingredients, a proton pump inhibitor and mosapride or pharmaceutically acceptable salts thereof, and to a core tablet composite formulation comprising an inner core and an outer layer part. The core tablet composite formulation according to the present invention comprises: an outer layer part comprising an enteric-coated pellet, which contains a proton pump inhibitor, and an inner core, which has a bilayer structure comprising a sustained release layer and an immediate release layer that contain, as an active ingredient, mosapride or a salt thereof.
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
17.
CORE TABLET PREPARATION COMPRISING PROTON PUMP INHIBITOR AND MOSAPRIDE
The present invention relates to a composite preparation in a core tablet form composed of an inner core comprising as an active ingredient at least one selected from the group consisting of esomeprazole, dexlansoprazole, and rabeprazole, and an outer layer part comprising mosapride as an active ingredient and having a bilayer structure of a sustained release layer and an immediate release layer. The composite preparation maintains pharmaceutical activities of esomeprazole and mosapride for 24 hours even at a single dosage per day.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines
The present invention pertains to a small-sized, sustained release pharmaceutical composition including choline alfoscerate as an effective component, and preparations of various dosage forms using same. A small-sized, sustained release choline alfoscerate preparation, for oral administration, prepared according to the present invention, uses a pharmaceutically acceptable sustained release substrate, and thus the elution of a drug is continuously maintained over a long period, reducing the number of times the drug is administered in a day. Also, in addition to reducing the number of times a drug is administered compared to conventional preparations, convenience of administration is improved by reducing the size of the individual preparations, and an improvement in treatment effect can be expected for patients taking a drug over a long period, compared to conventional preparations.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
The present invention provides a novel dosage form of a pharmaceutical composition containing choline alfoscerate. Further, the present invention provides pharmaceutical compositions containing choline alfoscerate and being both rapid-release and sustained-release, and by orally administering such rapid-release and sustained-release pharmaceutical compositions together it is possible to achieve sufficient pharmaceutical efficacy through only one dose a day.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
20.
Pharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer
Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.
The present invention relates to a sustained-release bilayer tablet of aceclofenac and a method for preparing same. The sustained-release bilayer tablet of aceclofenac according to the present invention is characterized by achieving a rapid pharmacological effect and obtaining a persistent effect even with once-daily administration. In addition, the sustained-release bilayer tablet of aceclofenac according to the present invention does not cause obstacles even in continuous mass production, and has excellent stability even in long-term storage.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
22.
METHOD FOR PREPARATION OF LEVODROPROPIZINE-CONTAINING, SUSTAINED-RELEASE TABLET
The present invention relates to a method for preparation of a levodropropizine-containing, sustained-release tablet composed of a sustained release layer responsible for delayed release, and an immediate release layer, each layer containing levodropropizine. When prepared by the method of the present invention, the levodropropizine-containing, sustained-release tablet is superb in terms of dissolution as well as formulation characteristics such as friability, hardness, preparation uniformity, and so on and thus exhibits excellent stability during long-term storage and transport.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
The present invention relates to a dry powder inhaler. The dry powder inhaler includes an inhaler housing, a drug container configured to be provided in the inhaler housing and accommodate the dry powder drug, a drug inlet configured to be disposed above the drug container and through which the dry powder drug is inhaled, and a mesh network configured to be installed on a path of the drug inlet and have a mesh part for collision with the dry powder drug formed therein.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The present invention relates to a sustained-release formulation of cilostazol, comprising cilostazol or a pharmaceutically acceptable salt thereof and, as a sustained-release matrix base, a neutral water-insoluble methacrylic acid copolymer.
The present invention relates to a solid preparation containing an extract of Pelargonium sidoides, and a preparation method therefor. The preparation according to the present invention contains a colloidal silicon dioxide as an excipient, and thus can be prepared in a solid form even without an adsorbent and a binder, and can be administered very conveniently while also exhibiting high stability, preservability and bioavailability.
The present invention relates to a sustained-release complex formulation comprising, as active ingredients, a statin-based drug which is an HMG-CoA reductase inhibitor, and cilostazol. More specifically, the sustained-release complex formulation consists of an HMG-CoA reductase inhibitor mixture part containing the HMG-CoA reductase inhibitor, and a cilostazol mixture part containing cilostazol, wherein the cilostazol mixture part contains immediate-release granules and sustained-release granules, and thus, the sustained-release complex formulation shows minimal side effects while allowing for immediate pharmacological activity, and has sustained-release properties which provide sufficient pharmacological effects even when orally administered only once daily.
The present invention relates to a complex formulation which comprises two active ingredients, Aceclofenac, an anti-inflammatory painkiller, and Esomeprazole, a proton-pump inhibitor, thereby minimizing the side effects caused by Aceclofenac while improving medication adherence and stability, and to a method of preparing same. A multilayered tablet complex formulation according to the present invention comprises a first active ingredient layer containing Aceclofenac or a pharmaceutically acceptable salt thereof, a second active ingredient layer containing Esomeprazole or a pharmaceutically acceptable salt thereof, and an inert layer not containing any active ingredient, wherein the structure in which the first active ingredient layer and the second active ingredient layer are separated from each other by the inert layer can prevent degradation and content loss attributable to the respective active ingredients being in physical contact with each other. Furthermore, the multilayered tablet complex formulation may further include a coating layer blocking external moisture on the outside of a tablet, thereby exhibiting excellent long-term stability.
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention pertains to: a liquid syrup preparation containing choline alfoscerate, potassium sorbate, and a corrigent; and a method for producing same. The liquid syrup preparation containing choline alfoscerate of the present invention is characterized by having excellent stability in that the formation of impurities caused by the decomposition of active ingredients is suppressed even during long-term storage, and being more convenient to administer due to improved flavor.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
29.
ENTERIC COATED TABLET COMPRISING FENOFIBRIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to an enteric coated tablet comprising fenofibric acid or a pharmaceutically acceptable salt thereof and to a manufacturing method therefor. The present invention can minimize the loss of a drug and increase the solubility of the drug, thereby maximizing bioavailability with even a small amount of the drug.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
30.
METHOD FOR PREPARING ORGANIC SOLVENT-FREE LYOPHILIZED CYCLOPHOSPHAMIDE
The present invention relates to a method for preparing a lyophilized cyclophosphamide composition, wherein 99% or more of the finally prepared lyophilized cyclophosphamide composition is reconstituted within 15 seconds when water for pharmaceutical use is injected thereinto at a ratio of 50 mL per 1 g of anhydrous cyclophosphamide, comprising a step of dissolving D-mannitol or lactose, as a lyoprotectant, and cyclophosphamide in a water solvent in a selected reaction vessel; and a lyophilized cyclophosphamide composition for injection prepared thereof.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
31.
METHOD FOR PREPARING LYOPHILIZED CYCLOPHOSPHAMIDE WITHOUT USING ORGANIC SOLVENT
The present invention relates to a method for preparing a cyclophosphamide lyophilized composition comprising a step of dissolving cyclophosphamide and D-mannitol or lastose as a lyophilization protector in water solvent in a reaction vessel at a selected temperature so that reconstitution over 99% is accomplished within 15 seconds upon injection of 50 mL of pharmaceutical water per gram of absolute cyclophosphamide for the finally prepared cyclophosphamide lyophilized composition, and to a cyclophosphamide lyophilized composition for injection prepared accordingly.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
32.
Pharmaceutical composition comprising THA as active ingredient for treating breast cancer
Provided is a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient, and a method for preventing, alleviating or treating breast cancer using the composition by inhibiting the activity of polo-like kinase 1 (PlK1).
Curcuma comosaCurcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.
The present invention relates to a composite preparation in a core tablet form, composed of an inner core containing rabeprazole as an effective ingredient; an outer layer portion including the bilayer structure of a sustained release layer and an immediate release layer and containing mosapride as an effective ingredient. The core tablet composite preparation according to the present invention is characterized by exerting sufficient pharmacological activity of rabeprazole and mosapride even upon administration of one tablet once a day.
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Drugs for medical purposes; pharmaceutical preparations;
bronchodilating preparations; nervines; analgesics;
antiseptics; febrifuges; chemical preparations for medical
purposes; albuminous foodstuffs for medical purposes; air
purifying preparations; anti-inflammatory analgesic
preparations; pharmaceutical agents affecting sensory
organs; pharmaceutical agents affecting peripheral nervous
system; anti-inflammatory and antipyretic preparations;
cardiovascular pharmaceutical preparations; pharmaceutical
preparations for tumor treatment; pharmaceutical
preparations acting on the central nervous system;
antibiotic preparations; chemotherapeutics; pharmaceutical
preparations for the treatment of inflammatory diseases.
36.
Oral complex preparation comprising fat-soluble drug and solid preparation coated with oil-proof material
The present invention relates to an oral complex preparation comprising: a capsule containing a fat-soluble first drug; and a solid preparation containing a second drug, the solid preparation being embedded into the capsule and including an oil-proof material coating layer on the surface thereof
The oral complex preparation of the present invention prepared by embedding the solid preparation including the oil-proof material coating layer on the surface thereof and containing the second drug into the capsule containing the fat-soluble first drug enables two types of drug ingredients to be simultaneously administered. At this time, the oral complex preparation of the present invention can independently transfer each of two types of the active ingredients to a desired region without loss of the active ingredients since the oral complex preparation by enabling the oil-proof material coating layer on the surface of the solid preparation to block elution of the active ingredients of the solid preparation by the fat-soluble first drug or occurrence of side effects with the fat-soluble first drug.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
A61K 31/232 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone ayant au moins trois doubles liaisons, p. ex. étrétinate
The present invention relates to a dry powder inhaler. The present invention relates to an inhaler for administering a dry powder medicine containing an active ingredient and a carrier, the inhaler comprising: an inhaler housing; a medicine accommodation part which is provided inside the inhaler housing and in which a dry powder medicine is accommodated; a medicine inhalation hole which is arranged at the upper part of the medicine accommodation part and in which the dry powder medicine is inhaled; and a mesh net which is provided on a path of a medicine inhalation hole and has a mesh part for collision with the dry powder medicine.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
38.
Composite preparation of mosapride and rabeprazole
The present invention relates to a composite preparation with various dosage forms comprising mosapride and rabeprazole.
The composite preparation prepared according to the present invention allows rapid release of a drug without deteriorating its release by an interaction between mosapride and rabeprazole, thus exhibiting an improved drug release rate and bioavailability, while having excellent product stability and being capable of significantly lowering the amount of the excipient. Accordingly, the composite preparation of the present invention can improve patients' drug compliance due to the size of its dosage form.
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient for preventing, alleviating, or treating breast cancer. More specifically, the composition of the present invention exhibits an excellent effect in the treatment of breast cancer by inhibiting the activity of polo-like kinase 1 (Plk1), and thus is expected to be used to prevent, alleviate, and treat breast cancer.
The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
41.
COMPOSITE PREPARATION CONTAINING CLOPIDOGREL AND ASPIRIN
The present invention relates to a composite preparation containing clopidogrel and aspirin and to a method for preparing the same, wherein the composite preparation has stability maintained even during storage and distribution and shows a fast clopidogrel tablet disintegration rate.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING (±)-2-[2-(3-CARBOXYPROPIONYLOXY)-3-DIMETHYLAMINOPROPOXY]-3'-METHOXYBIBENZYL OR SALTS THEREOF
One aspect of the present invention provides a pharmaceutical composition comprising (±)-2-[2-(3-carboxypropionyloxy)-3-dimethylaminopropoxy]-3'-methoxybibenzyl hydrochloride as an active ingredient.
The present invention relates to an oral composite formulation comprising: a capsule containing a first drug with fat solubility; and a solid preparation containing a second drug, the solid preparation being inserted inside the capsule and including an oil repellent base coating layer on a surface thereof. The oral composite formulation of the present invention, which comprises a capsule containing a first drug with fat solubility and a solid preparation inserted inside the capsule, the solid preparation including an oil repellent base coating layer on a surface thereof and containing a second drug, allows a simultaneous administration of two types of ingredient drugs, and here, the oil repellent base coating layer on the surface can prevent an active ingredient of the solid preparation from being released by the first drug with fat solubility and causing side reactions with the first drug with fat solubility, thereby delivering two types of active ingredients independently to desired sites without loss of the active ingredients, respectively.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
The present invention relates to a composite preparation, with various dosage forms, of mosapride and rabeprazole. The composite preparation prepared according to the present invention allows a rapid release of drug without the deterioration of release by an interaction of mosapride and rabeprazole, thereby exhibiting an improved drug release rate and bioavailability and having excellent product stability, and significantly lowers the excipient content, thereby improving drug compatibility of a patient due to the size of the dosage form.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
The present invention relates to a composite preparation containing clopidogrel and aspirin, and to a composite preparation having a capsule containing: a granule having a clopidogrel layer coated with an immediate-release protection layer; and an aspirin granule having an aspirin layer coated with an enteric layer. The present invention blocks physical contact between the clopidogrel and the aspirin, thereby fundamentally blocking an eutectic phenomenon, and thus, in the short-term, prevents changes in the amount, elution properties and bioequivalence of the preparation, and in the long-term, enhances the stability of the preparation, and also has the effect of preventing damage to the stomach wall by having the aspirin coated with an enteric layer. Further, a damp-proofing coating layer is included in order to enhance the stability of the moisture-sensitive clopidogrel and salt thereof, and thus the generation of clopidogrel impurities is minimized without a change in the elution amount of the clopidogrel. Further, the present invention enables a marked decrease in the amount of residual solvent contained in the clopidogrel, even without going through an additional process in production such as a drying treatment, and thus has the effect of cutting production costs through a simple process.
The present invention relates to a sustained-release cilostazol preparation, the sustained-release preparation of the present invention showing an elution profile that can effectively maintain drug concentration in vivo while showing an adequate early elution rate, thereby enabling the effects of maintaining the medicinal effect of cilostazol through one intake per day while decreasing the expression of side effects, and also improving medication compliance.
The present invention relates to a use of a mixture extract of Coptidis rhizome and Pelargonium Sidoides as an antitussive or expectorant agent, and a use of the same for preventing or treating respiratory diseases or respiratory infection.
본 발명은 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물에 관한 것으로서, 보다 구체적으로는 금제제를 포함하는 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명의 약학적 조성물은 금(gold)제제를 유효성분으로 포함함으로써, 대식세포의 M2 형질전환을 촉진시킬 뿐만 아니라, TREM-2 발현 증가로 성상세포의 활성화를 억제하여 간 섬유화 또는 간 경화를 예방, 치료 또는 개선하는 약학 조성물, 식품 조성물 등으로 유용하게 이용될 수 있을 것으로 기대된다. 또한, 금(gold)제제, 특히 오라노핀(auranofin)과 이와 유사한 금티오말산 소듐(sodium aurothiomalate) 또는 금티오글루코오스(aurothioglucose)는 타 용도(류마티스 관절염)로 이미 상당 기간 사용되어 왔기 때문에, 약물들에 의한 부작용 가능성이 낮은 장점도 있다.
The present invention relates to a pharmaceutical combined preparation containing an omega-3 fatty ester and a statin-based drug. The oral combined preparation according to the present invention contains, a tablet containing a statin-based drug, inside a capsule agent containing an omega-3 fatty acid ester, and thus, the oral combined preparation is fundamentally and completely cut off from contact with an external environment, including moisture, low pH, and the like, thereby showing high stability and excellent disintegration and dissolution rates.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
52.
Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
The formulation for oral administration of the present invention containing Mosapride or its salt is a double layer formulation consisting of a fast-release layer for rapid release of a drug and a sustained-release layer for slow release in order to simultaneously satisfy the rapid exhibition of pharmacological activities and sustained maintenance of pharmacological activities for 24 hours, wherein the high-viscosity hydroxypropyl methylcellulose (HPMC) and the low-viscosity HPMC are used in mixture such that the content of a high viscosity HPMC as a controlled-release matrix within the sustained-release layer has a higher content, thereby capable of controlling the dissolution rate in the regions having different pH values within the gastrointestinal tract and/or the retention time in the gastrointestinal tract. Additionally, the formulation of the present invention is a small-sized preparation with a total weight of 200 mg or less, preferably from 150 mg to 160 mg, thus capable of improving drug compliance of patients.
The present invention relates to a solid preparation comprising choline alfoscerate and calcium silicate and a method for preparing the same, wherein calcium silicate adsorbs choline alfoscerate and thereby enables formulation in a solid form. Compared to soft capsule formulations, the solid preparation of the present invention, comprising choline alfoscerate and calcium silicate, has advantages of there being less concern regarding deterioration due to microorganisms and stability degradation due to moisture, and of being excellent in the ease of dosing because of a smaller volume. In addition, the present invention improves the initial dissolution rate of the solid preparation by using two or more disintegrants by mixture and thereby exhibits the same level of dissolution profile as conventional soft capsule formulations, and therefore is not different therefrom in the expression of a medicinal effect.
The present invention relates to a solid preparation including a Pelargonium sidoides extract and a silicic acid compound, which is allowed to be formulated in a solid form by direct adsorption of the Pelargonium sidoides extract onto a silicic acid compound, and a preparation method thereof. Since the solid preparation including the Pelargonium sidoides extract and the silicic acid compound of the present invention has higher stability than a liquid preparation such as syrup, and has no additives such as sugars, there is no concern about microbial contamination or spoilage of the preparation. In addition, it is possible to pack the solid preparation individually. Since the solid preparation is smaller in volume than the liquid preparation, it is highly portable, and there is also a convenience that no additional tools are needed to take the drug. Further, the active ingredient can be taken at the equal amount every time.
The present invention relates to an oral formulation having masked bitter taste, which comprises an extract of Coptis rhizome and a cation-exchange resin having a sulfonic acid group, and to a preparation method thereof.
A preparation for oral administration of the present invention, containing mosapride or salt thereof, is a double-layer preparation consisting of an immediate-release layer which allows drug to be rapidly released, and a sustained-release layer which allows drug to be slowly released, in order to simultaneously satisfy a rapid expression of pharmacological activity and a 24-hour duration of pharmacological activity, and is characterized by controlling a dissolution rate of each site within the gastrointestinal tract with different pHs and/or a residence time in the gastrointestinal tract by using, in a mixed manner, high viscosity hydroxypropyl methylcellulose (HPMC) and low viscosity hydroxypropyl methylcellulose (HPMC) in such a manner that the proportion of high viscosity hydroxypropyl methylcellulose (HPMC), as a release-control base in the sustained-release layer, is higher. Furthermore, the preparation of the present invention has a small size with a total weight of 200 mg or less, preferably 150 to 160 mg, and thus, has the advantage of increasing a patient's medication adherence.
A powder material inhaler, according to the present invention, comprises: a main body having a hollow shape; a powder receiving unit which is coupled with one open side of the main body and receives a powder material in a sealed state through a protection membrane; and an inhalation body which is slidably coupled with the other open side of the main body. The present invention is a portable device having a simple structure and enables a user to conveniently take powdered drugs for respiratory therapy which are stored in the sealed state by a simple operation thereof.
The present invention relates to a composite composition containing amlodipine and rozaltan, and having improved stability by comprising an antioxidant.
The present invention relates to a sustained release tablet of levodropropizine consisting of an immediate release layer, which includes levodropropizine, and a sustained release layer, which includes levodropropizine and a polymer for controlling release.
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
60.
CHEWABLE SILDENAFIL CITRATE TABLETS IN WHICH BITTERNESS IS MASKED, AND PRODUCTION METHOD THEREFOR
The present invention relates to a method for producing chewable tablets of sildenafil citrate, a therapeutic agent for erectile dysfunction, in which the bitterness of the sildenafil citrate is masked and which are easy to take, and the invention provides chewable sildenafil citrate tablets in which the bitterness is masked by the use of an ion-exchange resin having a carboxyl group. The chewable sildenafil citrate salt tablets produced in accordance with the present invention are outstanding in terms of rapidity of elution and concealment of bitterness, and are easy to take and can therefore be expected to be very useful when administered to patients.
The present invention relates to a complex agent of clopidogrel and aspirin, and more particularly, to a complex agent including a capsule containing a granule obtained by coating a clopidogrel layer with a layer for preventing rapid release, and an aspirin granule obtained by coating an aspirin layer with a enteric layer. The physical contact between the clopidogrel and the aspirin may be blocked, and the eutectic phenomenon may be fundamentally blocked. In the short term, a change in the amount, elution properties, and bioequivalence of the agent may be prevented, and in the long term, the stability of the agent may be ensured. In addition, damage to the stomach wall may be prevented by coating the aspirin with the enteric layer.
A61K 31/4743 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant le soufre comme hétéro-atome d'un cycle
62.
CONTROLLED-RELEASE ORAL COMPOSITION CONTAINING ITOPRIDE HYDROCHLORIDE, AND PREPARATION METHOD THEREOF
The present invention relates to a preparation method of an extended release tablet containing itopride hydrochloride as an active ingredient, and more specifically, the present invention provides an extended release tablet in which dissolution is extended for enabling administration of one dose per day, thereby improving administration convenience and compliance when compared to existing commercial preparations which are taken three times a day. The itopride extended release tablet according to the present invention can effectively control the release of itopride hydrochloride with a velocity close to zero order for 24 hours without the deviation of dissolution, and thus the inconvenience of taking three doses per day can be solved by taking only one dose per day. In addition, since the weight per tablet is 450 mg and the size of a tablet is small, the compliance of a patient is high, thereby preventing the loss of efficacy or the worsening of symptoms.
The present invention relates to a composition for the controlled-release of drugs. More particularly, the composition for the controlled-release of drugs according to the present invention expands the capacity for the controlled-release of a matrix-type polymer for controlled-release via a carbomer in which said polymer for controlled-release forms a basic frame and in which sol-gel transition occurs in accordance with a pH level. The composition of the present invention is characterized in that it comprises: a solubilizing agent for the event the drug to be released is highly insoluble, and a disintegrating agent for sufficient initial release. The composition for the controlled-release of drugs according to the present invention uses a carbomer which maintains the controlled-release of conventional matrix structures having polymers for controlled-release and which has sol-gel transition properties, thus preventing a sudden release of a drug caused by a collapse of the matrix structure during a late stage of elution. In addition, the composition of the present invention uses a solubilizing agent to solve the problem of a highly insoluble drug failing to dissolve even after being released, and also uses a disintegrating agent to improve the speed of the initial release, which is the limiting factor in controlled-release preparations.
Provided is a slow-release tablet including cilostazol as a pharmacologically active component, which is efficacious in suppressing aggregation of blood platelets and promoting vascular relaxation by inhibiting phosphodiesterase types. The slow-release cilostazol tablet has an extended elution time so that the slow-release cilostazol tablet can be taken once daily for convenience of drug use, and minimizes the manifestation of headache which is one side effect caused when women, the elderly and children take conventional cilostazol preparations so that the convenience of drug use can be improved. Also, the slow-release cilostazol tablet exhibits a stable elution pattern with no variation in elution rate according to changes in pH in the stomach and intestines, as well as an effect of delaying the release of a drug, using a mixture of hydroxypropyl methylcellulose and a carbomer as a release-controlling polymer.
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
65.
ACECLOFENAC SLOW-RELEASE PREPARATION PROVIDING AN OPTIMUM PHARMACOLOGICAL CLINICAL EFFECT WHEN ADMINISTERED ONCE A DAY
The present invention relates to a controlled-release preparation administered orally once a day that exhibits an optimum pharmacological clinical effect, featuring two-layer tablets, dual tablets and multilayered tablets having a fast-release layer comprising aceclofenac, a water-soluble additive, a non-soluble additive, a solubilizer, a disintegrator and a filler, and a slow-release layer comprising aceclofenac, a slow-release base, a disintegrator, a binder, a filler, a fluidizer, a solubilizer and a lubricant.
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
66.
SLOW-RELEASE CILOSTAZOL TABLET HAVING AN IMPROVED ELUTION RATE AND MINIMAL SIDE EFFECTS
The present invention relates to a slow-release tablet of cilostazol which is a pharmacologically active component efficacious in the suppression of blood platelet aggregation and the promotion of vascular relaxation by inhibiting phosphodiesterase types; and, more specifically, provided is a slow-release cilostazol tablet of which the elution time is extended such that it can be taken once a day for expediency of drug-taking, and which minimises the occurrence of headache which is a side effect during the taking of cilostazol preparations of the prior art and therefore improves the convenience of drug-taking for women, the elderly and children. Also provided is a slow-release cilostazol tablet which exhibits a stable elution pattern without any variation in the percentage eluted depending on the pH in the stomach in addition to an effect whereby release of the drug is delayed, by using a release-controlling polymer consisting of a mixture of hydroxypropyl methyl cellulose and a carbomer.
A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
67.
MULTIFUNCTIONAL CONTRAST AGENT USING BIOCOMPATIBLE POLYMER AND PREPARATION METHOD
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (République de Corée)
KOREA UNITED PHARM. INC. (République de Corée)
Inventeur(s)
Cho, Sun Hang
Shin, Byung Cheol
Yuk, Soon Hong
Seong, Ha Soo
Kim, Byung Jin
Kim, Hyo Jeong
Choi, Youn Woong
Min, Byung Gu
Ha, Dae Chul
Abrégé
The present invention relates to a biocompatible contrast agent and a method of its preparation. More particularly, the present invention relates to a multifunctional contrast agent manufactured by prepairing a novel polysuccinimide-based polymer by introducing an alkanolamine group to the main group of the pioysuccinimide in addition to a biocompatible hydrophilic group, which improves bioavailability, and a hydrophobic group, which enables to maintain the form of stable nanoparticles during the formation of nano particles for a long period of time and to encapsulate a hydrophobic anticancer agent.
C08G 73/10 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide-acides ou précurseurs similaires de polyimides
C08G 73/00 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant de l'azote, avec ou sans oxygène ou carbone, non prévus dans les groupes
A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
Disclosed herein are single-layer and double-layer tablets, which release aceclofenac in a controlledmanner so as to achieve ideal drug release close to a straight line. Also, the tablets promote drug absorption in the stomach by controlling pH, contain aceclofenac with improved stability and haveboth immediate-release properties and sustained-release properties. Specifically, provided is an aceclofenac sustained-release tablet which is composed of an immediate-release layer containing aceclofenac, a water-soluble additive, a pH-controlling agent, a disintegrant, a filler and a lubricant and of a sustained-release layer containing aceclofenac, a release-controlling polymer, an oil-soluble surfactant, a filler and a lubricant, wherein the pH-controlling agent is sodium hydrogen carbonate, and the release-controlling polymer is a mixture of hydroxypropylmethylcellulose and carbomer.
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61K 9/54 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue contenant des particules distinctes avec des revêtements de différentes épaisseurs ou de différents matériaux
69.
ORAL SOFT CAPSULE OF ACECLOFENAC HAVING IMPROVED STABILITY
The present invention relates to an aceclofenac-containing soft capsule formulation having improved stability and the preparation thereof, and more particularly to a method of preparing a soft capsule by dissolving or dispersing aceclofenac, which is unstable in an aqueous solution, in oil or a mixture of oils. The aceclofenac-containing soft capsule contains an aceclofenac-containing liquid composition prepared by mixing and solubilizing aceclofenac, oil and a suspending agent. The soft capsule can maintain stability for 3 years or more and has improved active ingredient dissolution compared to existing soft capsules, thus increasing the bioavailability of the active ingredient.
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
A61K 9/52 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue
A61K 9/64 - Revêtements organiques contenant des protéines ou leurs dérivés
A61K 9/66 - Préparations en capsules, p. ex. de gélatine, de chocolat du type à libération prolongée ou discontinue contenant des émulsions, dispersions ou solutions
70.
METHOD FOR THE PREPARATION OF BIOCOMPATIBLE POLYMERIC NANOPARTICLES FOR DRUG DELIVERY AND NANOPARTICLES PREPARED THEREBY
HANNAM UNIVERSITY INSTITUTE FOR INDUSTRY-ACADEMIA COOPERATION (République de Corée)
KOREA UNITED PHARM. INC (République de Corée)
Inventeur(s)
Yuk, Soon Hong
Oh, Keun Sang
Jung, Won Tae
Ahn, Seong Woo
Ha, Dae Chul
Cho, Sang Min
Choi, Youn Woong
Kim, Do Hyung
Choi, Jeong Hyun
Abrégé
Disclosed are biocompatible polymeric nanoparticles for drug delivery and a method for preparing the same. They can be prepared by mixing a tri-block copolymer, PEG, and a drug at a predetermined temperature to give a homogeneous polymeric mixture; solidifying the homogeneous polymeric mixture at room temperature; and dissolving the solidified polymeric mixture in an aqueous solution. Based on a polymer melting process, the method makes it easy to produce poloxamer nanoparticles at low cost. The nanoparticles show desired particle sizes suitable for use in drug delivery and a uniform particle size distribution. Consisting of a bilayer structure, the nanoparticles can contain sparingly soluble drugs. Also, the nanoparticles contain no organic solvents and are thus safe to the body because they are free of organic solvent residuals. Further, after being administered into the body, the nanoparticles with a high content of sparingly soluble drug entrapped therein can safely deliver the drug to target sites and stably release the drug at a controlled rate.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
